Matthew Correa

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma.

L. Hamann, L. LeBrun, B. Cathers, 2020, Journal of medicinal chemistry.

CC-90009: A Cereblon E3 Ligase Modulating Drug That Promotes Selective Degradation of GSPT1 for the Treatment of Acute Myeloid Leukemia.

L. LeBrun, B. Cathers, M. Pourdehnad, 2021, Journal of medicinal chemistry.

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

Discovery of mammalian target of rapamycin (mTOR) kinase inhibitor CC-223.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

Protein Degradation via CRL4CRBN Ubiquitin Ligase: Discovery and Structure-Activity Relationships of Novel Glutarimide Analogs That Promote Degradation of Aiolos and/or GSPT1.

Chin-Chun Lu, L. LeBrun, Alexander L. Ruchelman, 2017, Journal of medicinal chemistry.

Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005.

E. Hur, Lisa Morrison, B. Bennett, 2021, Journal of medicinal chemistry.

GTP binds to α-crystallin and causes a significant conformational change.

J. A. Mendoza, G. Zardeneta, Matthew Correa, 2012, International Journal of Biological Macromolecules.

Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.

P. Worland, D. Mortensen, B. Cathers, 2015, Journal of medicinal chemistry.

Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation.

D. Mortensen, L. Tehrani, Dehua Huang, 2023, Journal of medicinal chemistry.